30 results about "HGF Receptor" patented technology

The invention relates to five-membered heterocycle pyrimidine compounds, their pharmaceutical acceptable salt or pharmaceutical acceptable solvate and a preparation method thereof. The five-membered heterocycle pyrimidine compounds possess a c-Met inhibitory activity and have a structure as shown in the general formula 1. The invention also relates to a drug combination which contains the compounds and applications of the compounds in preparation of drugs used for prevention and treatment of in vivo Hepatocyte Growth Factor Receptor (HGFR) related abnormal cell proliferation, morphologic change and hyperkinesis associated diseases, angiogenesis or cancer metastasis associated diseases, and especially for prevention and treatment of tumor growth and metastasis.

The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions

The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions

The invention relates to a pyridine chemical shown as the following general formula and having c-Met and/or ALK inhibitory activity and its pharmaceutically-acceptable salt or pharmaceutically-acceptable solvate, a preparation method thereof, a pharmaceutical composition containing the chemicals, and applications of the chemicals in preparation of medicines for preventing and treating abnormal proliferation and morphological change of cells and related diseases, such as hyperkiesis, related to hepatocyte growth factor receptor (HGFR) and/or anaplastic lymphoma kinase (ALK) in organism and diseases related to vascularization or cancerometastasis, especially application in preparation of medicines for treating and preventing growth and metastasis of tumor.

This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Provided is an aptamer including a polynucleotide of any of the following (a) to (c) and capable of binding to an HGF receptor to exhibit an activity of inhibiting the binding of HGF to the HGF receptor. (a) A polynucleotide consisting of a base sequence set forth in SEQ ID NO: 1, (b) A polynucleotide consisting of a base sequence having the deletion, substitution, insertion and/or addition of one to several bases in the base sequence set forth in SEQ ID NO: 1, and (c) A polynucleotide consisting of a base sequence having a sequence identity of 80% or more to the base sequence set forth in SEQ ID NO: 1.

The invention relates to a quinoline compound which is used as a c-Met depressant and is expressed by the general formula (I) below, a pharmaceutically acceptable salt or pharmaceutically acceptable solvate and a preparation method of the compound, a medicament combination containing the compound and application of the compounds in the preparation of medicaments for preventing or treating diseases relevant to abnormal cell proliferation, morphological change and hyperkinesia with respect to hepatocyte growth factor receptors (HGFR) in an organism as well as diseases relevant to angiogenesis or cancerometastasis, especially medicaments for treating or preventing growth and metastasis of tumors.

The invention relates to a quinoline or quinoxaline compound shown as a following general formula I, pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof, and a preparation method thereof. The invention further relates to pharmaceutical composition containing the compound and / or pharmaceutically acceptable salt and / or pharmaceutically acceptable solvate thereof, and application of the pharmaceutical composition containing the compound and / or pharmaceutically acceptable salt and / or pharmaceutically acceptable solvate thereof to preparation of medicaments for preventing or treating diseases related to abnormal propagation, morphology and of cells and hyperkinesia that are related to hepatocyte growth factor receptor (HGFR) in organism, and diseases related to angiogenesis or cancerometastasis, and especially medicaments for preventing or treating tumour growth and cancerometastasis.

An antiviral agent consisting of hepatocyte growth factor (HGF) or an agonist of the HGF receptor, and a medicament for prophylactic and/or therapeutic treatment of a disease caused by hepatitis C virus comprising using said agent simultaneously or separately with other anti-viral agent.

Provided is a method for preparing hepatocytes or cells that can be differentiated into hepatocytes from pluripotent stem cells for the purpose of preparing mature hepatocytes that are similar in manyrespects to primary cultured hepatocytes, wherein the method is characterized by including (1) a step for culturing pluripotent stem cells in a medium that contains an activator of activin receptor-like kinase-4,7, (2) a step for culturing the cells obtained in step (1) in a medium that contains an osteogenic factor and a fibroblast growth factor, (3) a step for culturing the cells obtained in step (2) in a medium that contains a hepatocyte growth factor receptor activator and an oncostatin M receptor activator, and (4) a step for culturing the cells obtained in step (3) and obtaining hepatocytes or cells that can be differentiated into hepatocytes, at least one of steps (2), (3), and (4) involving culturing the cells on a high-density collagen gel membrane.

Provided is a method for producing intestinal cells derived from pluripotent stem cells, the produced intestinal cells exhibiting functions which are similar to those of actual intestinal cells. This method for producing intestinal cells uses a culture for differentiation into intestinal cells, which is characterized by containing a GSK3 inhibitor and one type selected from the group consisting of an activating agent for hepatocyte growth factor receptors, adrenal cortex hormone, calcitriol, and dimethyl sulfoxide.